The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to BravoVax Co., Ltd located in Wuhan, China.
Document
Prospective Grant of an Exclusive Patent License: Concatenated L2 Peptide Based Human Papillomavirus Vaccines
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent lice...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 56621
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of an Exclusive Patent License: Concatenated L2 Peptide Based Human Papillomavirus Vaccines,” thefederalregister.org (November 29, 2017), https://thefederalregister.org/documents/2017-25744/prospective-grant-of-an-exclusive-patent-license-concatenated-l2-peptide-based-human-papillomavirus-vaccines.